ASCO 2025 - Complete program listing (12)

Stay tuned for upcoming post-ASCO interviews and commentary

Daily recaps and interviews from the ASCO 2025

Dr. Kim Ma shares post-ASCO reflections on the evolving landscape of hormone therapy in metastatic hormone receptor–positive breast cancer, highlighting exciting advancements shaping treatment strategies ahead.

Dr. Ana Lohmann reviews her ASCO 2025 poster on recurrence patterns across breast cancer subtypes in the CCTG MA.32 trial, highlighting the ongoing risk of late recurrence in luminal BC and persistent risk of second primaries in all breast cancer subtypes .

Dr. Angela Toss reviews findings from an international cohort study presented at ASCO 2025, exploring how different types of BRCA1/2 pathogenic or likely pathogenic variants impact outcomes in young patients with breast cancer.

Dr. Marina De Brot presents their work showcased at ASCO 2025 on using AI to improve detection of HER2-low and HER2-ultralow breast cancer, enhancing diagnostic accuracy and expanding eligibility for HER2-targeted treatments.

Dr. Tara Sanft discusses findings from the BCI Registry Study presented at ASCO 2025, highlighting how the Breast Cancer Index influences treatment decisions in a prospective real-world setting.

Dr. Susan Dent reviews data impacting women with advanced breast cancer, comparing interim results from DESTINY-Breast09 to the CLEOPATRA standard. She addresses questions around time on therapy, practice change, and the importance of individualized, patient-centered care.

Drs. Jamil Asselah and Kim Ma return to discuss the latest ASCO 2025 data, focusing on SERENA-6 PFS outcomes and DESTINY-Breast09, where T-DXd plus pertuzumab sets a new first-line standard in HER2+ mBC with practice-changing impact.

Dr. Jamil Asselah speaks with Dr. David Cescon about results from the ASCENT-04 trial presented at ASCO 2025, discussing current standards of care, safety data, and the impact of these findings on clinical practice.

Drs. Jamil Asselah and Pedro Moraes review key data from SERENA-6 and ASCENT-04 presented at ASCO 2025, discussing whether the results are practice-changing and reflecting on their impact and interpretation from a global perspective.

Prof. Rebecca Dent highlights practice-changing data from ASCO 2025, including emerging therapies with different side effect profiles and new monitoring strategies in ER+ mBC. She reflects on the SERENA-6 plenary not just as data, but as a concept shaping the future of care, and shares key takeaways from her own DB-06 biomarker analysis of T-DXd vs TPC.

Dr. Susan Dent highlights her focus on cardiovascular health in breast cancer care, reviewing ASCO 2025 data on cardiotoxicities linked to modern cancer therapies and the need for proactive cardio-oncology strategies.

Drs. Jamil Asselah and Kim Ma recap Day 1 of ASCO 2025, where the focus was strongest on hormone receptor–positive breast cancer, highlighting updated INAVO120 survival data and what’s ahead for Day 2.